BDNF (Brain-Derived Neurotrophic Factor) exists in two forms: proBDNF and mature BDNF. Recent research has shown that these two forms can serve as potential biomarkers in plasma, providing insights into various neurological and psychiatric conditions.
ProBDNF is the precursor form of BDNF and is proteolytically cleaved to produce mature BDNF. Both forms are released into the bloodstream, allowing for their detection and measurement in plasma samples. The balance between proBDNF and mature BDNF has been implicated in different physiological and pathological processes.
Studies have suggested that alterations in the proBDNF to mature BDNF ratio may be indicative of neurological and psychiatric disorders. Increased levels of proBDNF or an imbalance between proBDNF and mature BDNF have been associated with conditions such as depression, schizophrenia, Alzheimer's disease, and Parkinson's disease. These findings suggest that dysregulation of BDNF processing and release may contribute to the pathogenesis of these disorders.
Measurement of proBDNF and mature BDNF in plasma offers a non-invasive method for assessing their levels and the balance between the two forms. This has the potential to serve as a valuable biomarker for diagnostic purposes, monitoring disease progression, and evaluating treatment responses in neurological and psychiatric conditions.